1. Introduction
===============

Concomitant primary malignant tumors of the female genital tract are rare. Most such cases are combined endometrial and ovarian cancer^\[[@R1]\]^ of unknown etiology and pathogenesis. It has been suggested that when embryologically similar tissues are concomitantly exposed to carcinogens or irritants, synchronous neoplasms may develop.^\[[@R2]\]^ In addition, the expression of the p53 tumor suppressor gene may increase the risk of a secondary tumor.^\[[@R3],[@R4]\]^ We present a rare case of concomitant malignancy of the endometrium and cervix.

2. Case report
==============

A 56-year-old female (gravidity 2; parity 2) with no significant medical history or any physical finding other than irregular vaginal bleeding presented to us for careful evaluation. Menopause had commenced at the age of 54 years. Physical examination revealed a soft abdomen, cervical atrophy, no contact bleeding, and no tenderness on palpation of the bilateral adnexa. The serum levels of carbohydrate antigen (CA)125, CA199, alpha-fetoprotein, and carcinoembryonic antigen were all within normal limits. The human papillomavirus (HPV) test (type 18/45) was positive. We performed dilation and curettage; pathology revealed a moderately differentiated endometrial carcinoma accompanied by squamous differentiation in the uterine cavity. The epithelium of the cervical uterus was atypical upon biopsy. We scheduled laparoscopic staging surgery including radical hysterectomy, bilateral adnexectomy, and pelvic lymphadenectomy. No dispersal of a malignant endometrial tumor was observed in the abdominal cavity. Both the pelvic and periaortic lymph nodes were normal when palpated.

Macroscopically, the uterus was approximately 7.5 × 4.5 × 3 cm in dimension; an endometrial tumor 1.2 × 1.0 × 0.5 cm in dimension was evident in the uterine cavity. On cutting, the tumor surface was predominantly solid in nature and gray in color, accompanied by obvious hemorrhage and necrosis, and invaded the superficial myometrium. No cervical mass was apparent. The bilateral adnexa were macroscopically normal.

Microscopically, the uterine cavity mass exhibited areas of crowded, complex, branching glandular structures, lined by stratified columnar epithelium. The extent of nuclear atypia was only moderate; the cytoplasm was eosinophilic and granular. Elsewhere, focal squamous differentiation was apparent. Histologically, the cervical pattern was complex; atypical neoplastic glands invaded the stroma. The neoplastic epithelium contained atypical neoplastic glands with enlarged, elongated hyperchromatic nuclei (Fig. [1](#F1){ref-type="fig"}). The cervical canal was normal, as were both fallopian tubes and ovaries. The pelvic lymph nodes were negative.

![Microscopic photograph of endometrial and cervical adenocarcinoma. The endometrial carcinoma comprised crowded, complex, branching glandular structures (A 50×, B 100×, C 200×) with moderate uclear atypia (D 400×). The cervical adenocarcinoma invaded the stroma (E 50×, F 100×). The neoplastic epithelium contained atypical neoplastic glands (G 200×) with enlarged, elongated hyperchromatic nuclei (H 400×).](medi-97-e9596-g001){#F1}

Immunohistochemically, the tumor in the uterine cavity was positive for the estrogen receptor (ER), progesterone receptor (PR), and vimentin; and was partial positive for p16, with a high ki67 index. However, the tumor in the uterine was diffusely positive for p16, but was negative for ER, PR, and vimentin (Fig. [2](#F2){ref-type="fig"}). Thus, we diagnosed the patients with endometrial carcinoma (Grade 2) concomitant with cervical adenocarcinoma (of the usual type).

![The immunochemical photograph of endometrial and cervical adenocarcinoma. P63 (A, F 200×), vimentin (B, G 200×), ER (C, H 200×), PR (D, I 200×), Ki67 (E, J 200×) stained in the tumor cells of endometrial adenocarcinoma (A--E). The different staining pattern was observed in the neoplastic glands of cervix (F--J). ER = estrogen receptor, PR = progestrogen receptor.](medi-97-e9596-g002){#F2}

3. Discussion
=============

Tumors are defined as synchronous when they develop concomitantly. Synchronous primary genital cancers are rare, constituting only 1% to 6% of all genital tract neoplasms.^\[[@R5]\]^ Single neoplasms or metastatic tumors of the cervix, endometrium, or ovary are more common. To date, only 6 cases of concomitant endometrial and cervical cancer have been reported.^\[[@R5],[@R6],[@R11]\]^

We report a case of mixed endometrial carcinoma in a 56-year-old female, accompanied by cervical adenocarcinoma, which is unusual. Patients with endometrial cancer are at markedly higher risk of concomitant breast, fallopian tube, ovarian, cervical, and colon cancer.^\[[@R7]\]^ Accurate differential diagnosis of primary and metastatic tumors is essential, because both the treatment and outcomes significantly differ.

The treatment strategy depends on age, initial cancer stage and grade, the extent of myometric lymphatic invasion, and lymphatic metastasis status. Tumor staging is the most important factor when evaluating the prognosis of endometrial cancer. FIGO recommends that when endometrial carcinoma attains the cervix, the cancer should be staged as II.^\[[@R8]\]^ The standard treatment for endometrial cancer is hysterectomy, bilateral salpingo-oophorectomy, and further surgical staging. Grade 1 or 2 cancers with minimal myometrial infiltration are low risk, and no treatment is required. Those with suspected cervical stromal invasion and lymphovascular involvement may require adjuvant radiation therapy.^\[[@R9]\]^

Malignant cervical glandular lesions are less common than squamous cell carcinoma, and are difficult to diagnose upon routine inspection.^\[[@R10]\]^ Although the tumor may attain the uterine cavity, neither tumor staging (IB1) nor prognosis is affected. Both the optimal treatment for cervical adenocarcinoma and prognosis remain unclear. Radical hysterectomy has been recommended for those with stage IB1 cervical cancer.^\[[@R11]\]^ Patients with high-level risk factors require extensive adjuvant radiotherapy.

Most reported contemporaneous primary neoplasms are of early stage and low-grade, as in our case.^\[[@R6]\]^ Many studies have shown that patients with contemporaneous early/low-grade endometrial and ovarian carcinomas survive better than those with more advanced metastatic malignancies.^\[[@R12],[@R13]\]^ One patient with both endometrial and cervical cancer exhibited no recurrence over 2 years of follow-up after comprehensive treatment. If preoperative diagnosis of a cervical glandular lesion fails, radiotherapy after surgery is required as rescue treatment^\[[@R14]\]^

However, the origin of the tumor of our present case remains debatable because of the histological features. In endometrial cancer, ER status may be the predominant element increasing the underlying risk for multiple cancers, whereas HPV is associated with the development of cervical and vaginal lesions.^\[[@R15]\]^ The expression of ER, PR, and vimentin indicated that the tumor was of endometrial origin. However, the absence of hormone receptors from the cervix accompanied by diffuse p16 reactivity favored a cervical origin. Moreover, the low-grade histology indicated a multifocal, primary sporadic cancer. Therefore, we considered that the patient had contemporaneous malignancies of the endometrium and cervix.

4. Conclusion
=============

In conclusion, our patient had independent primary endometrial and cervical tumors distinguishable both clinicopathologically and immunohistochemically. Concomitant primary gynecological cancers are uncommon; thus, more case reports are required to define the most appropriate treatment.

Abbreviations: AFP = alpha-fetoprotein, CA125 = carbohydrate antigen, CA199 = carbohydrate antigen, CEA = carcinoembryonic antigen, ER = estrogen receptor, HPV = human papillomavirus, PR = progesterone receptor.
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